“…The resultant cells, known as induced pluripotent stem (iPS) cells, were developed via retroviral delivery of various transcription factors (e.g., Oct3/4, Sox2, c-Myc, and Klf4) to adult dermal fibroblasts [ 18 , 19 , 20 ], hepatocytes, gastric epithelial cells, and even neural stem cells [ 21 , 22 ]. However, the practicality of utilizing different stem cells in clinical settings remains limited due to the ethical and safety concerns over their source [ 23 ]. In addition, current protocols for inducing differentiation into specific cell lineages are inefficient, time-consuming, technically complex, and are not cost effective given the requirement for multiple induction materials [ 24 , 25 ].…”